<DOC>
	<DOCNO>NCT00004245</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase I trial study effectiveness sodium salicylate treat patient advanced myelodysplastic syndrome , acute myelogenous leukemia chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Sodium Salicylate Treating Patients With Advanced Myelodysplastic Syndrome , Acute Myelogenous Leukemia , Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate safety , toxicity , pharmacokinetics sodium salicylate patient advance myelodysplastic syndrome ; newly diagnose , relapse , refractory acute myelogenous leukemia ; relapse refractory chronic lymphocytic leukemia . - Define biologic characteristic influence likelihood clinical response drug patient population . OUTLINE : Patients receive oral sodium salicylate twice day . Intrapatient dose escalation de-escalation permit . Treatment continue 6 week absence unacceptable toxicity disease progression . Responding patient may continue receive sodium salicylate beyond 6-week period . Patients acute myelogenous leukemia follow end therapy . Patients myelodysplastic syndrome follow death progression leukemia . PROJECTED ACCRUAL : A total 20 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Sodium Salicylate</mesh_term>
	<mesh_term>Salicylsalicylic acid</mesh_term>
	<mesh_term>Salicylates</mesh_term>
	<mesh_term>Salicylic Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Relapsed refractory acute myelogenous leukemia OR Elderly patient newly diagnose acute myelogenous leukemia eligible standard therapy OR `` Highrisk '' myelodysplastic syndrome , include : Refractory anemia excess blast Refractory anemia excess blast transformation Chronic myelomonocytic leukemia OR Relapsed refractory chronic lymphocytic leukemia Not eligible transplant protocol MSKCC refuse transplant Not eligible high priority protocol ( e.g. , bone marrow transplantation ) PATIENT CHARACTERISTICS : Age : Over 18 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Platelet count least 25,000/mm^3 Hepatic : Bilirubin great 2.0 mg/dL Transaminase level less 3 time upper limit normal PT great 14 second PTT great 34.6 second Renal : Creatinine great 2.0 mg/dL OR Creatinine clearance great 60 mL/min Other : Not pregnant nursing No history abnormal bleeding unexplained bleeding disorder No history peptic ulcer disease No salicylate allergy No concurrent active malignancy No concurrent illness would preclude study assessment significant degree PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
</DOC>